News & Events

Published On: 10/31/2018

TARGET PharmaSolutions Initiates a New Community, TARGET-HBV, to Advance the Understanding of Hepatitis B

CHAPEL HILL, NC – (October 31, 2018) – TARGET PharmaSolutions, Inc., a company focused on real world evidence, is pleased to announce that it has started enrolling patients in TARGET-HBV.    

TARGET-HBV is an observational study that will conduct a comprehensive review of patients with chronic hepatitis B virus (HBV) infection.  TARGET-HBV plans to enroll up to 5,000 patients across a large network of academic and community sites in the United States to advance the understanding of hepatitis B.

Dr. Anna Lok, TARGET-HBV Scientific Advisor, explained “TARGET-HBV is timely given the renewed interest in finding a cure for hepatitis B. Chronic hepatitis B is characterized by fluctuations in virus replication and disease activity; thus, while guidelines exist, management of individual patients can be nuanced. Data on a large cohort of hepatitis B patients managed in the real-world will provide insights into the course of this disease and guide the use of future therapies.”

Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions, stated “We are very excited that we have started enrolling patients in our TARGET-HBV community. We have seen significant interest from investigative sites to participate in this important study, and we look forward to continuing to advance the understanding of this challenging disease.”

TARGET PharmaSolutions provides regulatory grade data and analysis that can be used throughout the pharmaceutical development and commercialization process.  The TARGET model organizes a community of stakeholders, including key scientific leaders, regulatory agencies, pharmaceutical manufacturers, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history, current treatment paradigm, and patient outcomes.  This model enables TARGET’s stakeholders to answer critical strategic and planning questions. 

About Target RWE

Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.

Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe and other non-U.S. locations. Target RWE’s datasets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Whether partners need consulting services, datasets, support for custom solutions or access to a large biorepository of disease agnostic patient samples, Target RWE strives to be the preferred choice.

For more information, visit


Kayla Slake
Marketing Manager

984.234.0268 ext 205